TECregen Successfully Closes CHF 10 Million Seed Financing and Appoints New Chairman
TECregen, a pioneering biotechnology firm based in Basel, Switzerland, has successfully completed a seed financing round securing CHF 10 million (approximately EUR 10.7 million). This significant funding milestone aims to expedite the company's innovative work in thymus regeneration, which seeks to restore immune function and enhance immune health across various stages of life.
The financing was led by the Boehringer Ingelheim Venture Fund (BIVF), with participation from renowned investors such as LifeSpan Vision Ventures, Carma Fund, EOS BioInnovation, High-Tech Gründerfonds (HTGF), the JFG Life Sciences Foundation from the University of Basel, and Zurich Cantonal Bank.
The capital raised will propel the development of TECregen's groundbreaking thymopoietic biologics, which focus on rejuvenating thymic epithelial cells (TECs). These therapies are designed not only to restore immune function but also to bolster overall immune resilience, which is increasingly crucial as populations age.
In conjunction with the financing announcement, TECregen revealed the appointment of Dr. Bo Rode Hansen, Ph.D., MBA, as the new Chairman of the Board of Directors. Dr. Hansen brings over two decades of experience in the biotech sector, having held senior positions in several prominent companies including Roche and Santaris Pharma. His leadership as CEO of Scandion Oncology A/S and founding President of Genevant Sciences further solidifies his reputation.
In his new role, Dr. Hansen is expected to guide TECregen toward achieving its strategic growth objectives while advancing the company’s thymus rejuvenation initiatives. Expressing his enthusiasm about joining TECregen at this critical juncture, he stated, "The team's pioneering work in thymus regeneration has the potential to redefine treatment approaches for immune aging and related diseases. I am excited to work closely with the talented management team and our supportive investors to expedite the development of transformative therapies that can benefit patients in need."
Filippo Oliveri, co-founder and Board Director of TECregen, welcomed Dr. Hansen, highlighting the value of his extensive industry experience. He stated, "His proven leadership will be crucial as we pursue our mission. With robust investor backing, TECregen is prepared to hasten its thymus regeneration efforts and bring forth innovative immune rejuvenation therapies to the market."
Dr. Philipp Müller, Investment Manager at BIVF, remarked on TECregen’s innovative approach, positioning the company at the forefront of targeted biologics aimed at restoring immune function. He noted that this pioneering ability to modulate and restore thymic function creates promising therapeutic opportunities in immunology, oncology, and rare diseases., underscoring the excitement around TECregen’s potential advancements toward clinical development.
TECregen’s unique approach to thymus rejuvenation aims to tackle conditions linked to impaired T-cell responses. By revitalizing and expanding TECs, the company seeks not only to replenish T cells but also to foster long-lasting improvements in immune function. Through the development of a differentiated pipeline of thymopoietic biologics, TECregen aspires to enhance immune recovery following transplants or cytotoxic therapies, uphold immune health, and support immune surveillance against cancer. This endeavor may usher in a new era of immunotherapy, heralding hope for patients facing severe immune challenges.
As TECregen stands poised for growth, the biotechnology community watches closely, anticipating the breakthroughs that could arise from their innovative research in thymus rejuvenation and immune restoration.
About TECregen
TECregen is dedicated to pioneering thymus rejuvenation to combat ailments arising from reduced T-cell functions. The company's leading-edge strategy focuses on revitalizing and expanding the population of thymic epithelial cells (TECs), aiming to replenish T cells and achieve long-term enhancements in immune capabilities. With a robust pipeline of innovative thymopoietic biologics under development, TECregen is committed to facilitating immune recovery post-transplantation and during cytotoxic treatments, promoting overall immune health and advancing immunotherapy’s frontiers.
The financing was led by the Boehringer Ingelheim Venture Fund (BIVF), with participation from renowned investors such as LifeSpan Vision Ventures, Carma Fund, EOS BioInnovation, High-Tech Gründerfonds (HTGF), the JFG Life Sciences Foundation from the University of Basel, and Zurich Cantonal Bank.
The capital raised will propel the development of TECregen's groundbreaking thymopoietic biologics, which focus on rejuvenating thymic epithelial cells (TECs). These therapies are designed not only to restore immune function but also to bolster overall immune resilience, which is increasingly crucial as populations age.
In conjunction with the financing announcement, TECregen revealed the appointment of Dr. Bo Rode Hansen, Ph.D., MBA, as the new Chairman of the Board of Directors. Dr. Hansen brings over two decades of experience in the biotech sector, having held senior positions in several prominent companies including Roche and Santaris Pharma. His leadership as CEO of Scandion Oncology A/S and founding President of Genevant Sciences further solidifies his reputation.
In his new role, Dr. Hansen is expected to guide TECregen toward achieving its strategic growth objectives while advancing the company’s thymus rejuvenation initiatives. Expressing his enthusiasm about joining TECregen at this critical juncture, he stated, "The team's pioneering work in thymus regeneration has the potential to redefine treatment approaches for immune aging and related diseases. I am excited to work closely with the talented management team and our supportive investors to expedite the development of transformative therapies that can benefit patients in need."
Filippo Oliveri, co-founder and Board Director of TECregen, welcomed Dr. Hansen, highlighting the value of his extensive industry experience. He stated, "His proven leadership will be crucial as we pursue our mission. With robust investor backing, TECregen is prepared to hasten its thymus regeneration efforts and bring forth innovative immune rejuvenation therapies to the market."
Dr. Philipp Müller, Investment Manager at BIVF, remarked on TECregen’s innovative approach, positioning the company at the forefront of targeted biologics aimed at restoring immune function. He noted that this pioneering ability to modulate and restore thymic function creates promising therapeutic opportunities in immunology, oncology, and rare diseases., underscoring the excitement around TECregen’s potential advancements toward clinical development.
TECregen’s unique approach to thymus rejuvenation aims to tackle conditions linked to impaired T-cell responses. By revitalizing and expanding TECs, the company seeks not only to replenish T cells but also to foster long-lasting improvements in immune function. Through the development of a differentiated pipeline of thymopoietic biologics, TECregen aspires to enhance immune recovery following transplants or cytotoxic therapies, uphold immune health, and support immune surveillance against cancer. This endeavor may usher in a new era of immunotherapy, heralding hope for patients facing severe immune challenges.
As TECregen stands poised for growth, the biotechnology community watches closely, anticipating the breakthroughs that could arise from their innovative research in thymus rejuvenation and immune restoration.
About TECregen
TECregen is dedicated to pioneering thymus rejuvenation to combat ailments arising from reduced T-cell functions. The company's leading-edge strategy focuses on revitalizing and expanding the population of thymic epithelial cells (TECs), aiming to replenish T cells and achieve long-term enhancements in immune capabilities. With a robust pipeline of innovative thymopoietic biologics under development, TECregen is committed to facilitating immune recovery post-transplantation and during cytotoxic treatments, promoting overall immune health and advancing immunotherapy’s frontiers.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.